The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial
Status:
Recruiting
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase III multicentre randomized controlled trial (RCT) to evaluate the impact of
tranexamic acid (TXA) on perioperative blood transfusion in patients undergoing liver
resection. The rationale for this study includes: (1) experimental evidence supporting the
use of TXA in other surgical populations; (2) lack of evidence in patients undergoing liver
resection; (3) clinical uncertainty and extensive support amongst hepatobiliary surgeons,
anaesthesiologists, and hematologists for this proposed trial; (4) a feasible and efficient
study design; and (5) the importance of the question: incidence of blood transfusion in
patients undergoing liver resection is high, and the consequences serious. The sample size
for this study is 1230 participants.Participants enrolled in the prior Vanguard study will
proceed directly into the RCT.